Core Insights - Shares in Zoetis have faced pressure following the release of its Q4 earnings report, which showed satisfactory numbers but disappointing revenue guidance for 2025 [1] - The revenue guidance for 2025 is influenced by various factors, including new market entrants and potential product approvals [2][3] Revenue Guidance Considerations - The operational organic revenue growth forecast for 2025 is projected at 6% to 8%, factoring in assumptions about new competitors entering the market [2] - The success of these new entrants remains uncertain, which could impact Zoetis' performance relative to management's expectations [2] Potential Upsides - Management's guidance does not account for products awaiting approval, with expectations for three pharmaceutical product approvals in the next 12 months, five in the next 12 to 36 months, and seven in the next 36 to 60 months [3] - The anticipated product approvals could contribute positively to revenue in 2025, with management expressing optimism about having at least one approval each year for the next several years [4] - Specifically, products targeting chronic kidney disease and oncology in dogs could open markets valued at up to $5.7 billion, representing significant growth potential for Zoetis [4]

Company Performance - Zoetis (ZTS) closed at $163.03, with a slight decrease of -0.08% from the previous trading session, underperforming the S&P 500 which gained 0.08% [1] - Over the last month, Zoetis shares increased by 3.65%, outperforming the Medical sector's decline of 1.03% and the S&P 500's loss of 7.33% [1] Upcoming Earnings - The upcoming earnings release is anticipated, with expected EPS of $1.41, reflecting a 2.17% increase from the prior-year quarter [2] - Quarterly revenue is projected at $2.19 billion, up 0.12% from the year-ago period [2] Full Year Estimates - For the full year, analysts expect earnings of $6.12 per share and revenue of $9.31 billion, indicating changes of +3.38% and +0.59% respectively from last year [3] Analyst Estimates - Recent changes in analyst estimates are crucial as they reflect near-term business trends, with positive revisions indicating confidence in the company's performance [4] Zacks Rank and Valuation - Zoetis currently holds a Zacks Rank of 4 (Sell), with a Forward P/E ratio of 26.68, which is a premium compared to the industry's average Forward P/E of 17.23 [6] - The Zacks Consensus EPS estimate has shifted 0.14% upward over the past month [6] PEG Ratio - The company has a PEG ratio of 2.86, compared to the Medical - Drugs industry's average PEG ratio of 0.99 [7] Industry Ranking - The Medical - Drugs industry, part of the Medical sector, has a Zacks Industry Rank of 82, placing it in the top 33% of over 250 industries [8]

Core Insights - The individual has extensive experience in financial markets, starting from 2007, with a background in economics and equity research [1] - The role as CFO for a holding company across various industries has provided valuable insights into company management and accounting practices [1] - The focus is on identifying high-quality companies with competitive advantages that can generate compounded cash flow at fair prices [1] Company Analysis - The investment strategy emphasizes profitable businesses operating in growing sectors with high returns on capital, expanding margins, and low debt [1] - Management's commitment is a key factor in evaluating potential investments, indicating a preference for companies where management has "skin in the game" [1] - A comprehensive analysis includes the company's business model, market dynamics, competition, financials, and management [1] Valuation Approach - Valuation measures such as multiples and discounted cash flow (DCF) analysis are applied to assess expected growth [1] - The investment approach is long-term, focusing on companies capable of deploying capital at high returns on invested capital (ROIC) for several years [1]

Company Performance - Zoetis (ZTS) closed at $170.37, reflecting a +1.87% increase from the previous day, outperforming the S&P 500's gain of 0.55% [1] - Over the last month, Zoetis shares decreased by 3.95%, underperforming the Medical sector's gain of 0.52% and the S&P 500's loss of 5.56% [1] Upcoming Financial Results - Zoetis is expected to report an EPS of $1.41, representing a 2.17% increase from the prior-year quarter, with anticipated revenue of $2.2 billion, indicating a 0.47% increase from the same quarter last year [2] Annual Estimates - For the annual period, earnings are projected at $6.12 per share and revenue at $9.31 billion, reflecting increases of +3.38% and +0.59% respectively from the previous year [3] Analyst Projections - Recent shifts in analyst projections for Zoetis should be monitored, as positive revisions indicate optimism about the company's business and profitability [3] Zacks Rank and Performance - The Zacks Rank system, which incorporates estimate changes, currently ranks Zoetis at 3 (Hold), with a recent downward shift of 3.83% in the consensus EPS estimate [5] - Historically, 1 ranked stocks in the Zacks Rank system have returned an average of +25% annually since 1988 [5] Valuation Metrics - Zoetis has a Forward P/E ratio of 27.35, which is a premium compared to the industry average of 19.2 [6] - The company also has a PEG ratio of 2.93, while the Medical - Drugs industry has an average PEG ratio of 1.06 [7] Industry Context - The Medical - Drugs industry, part of the Medical sector, holds a Zacks Industry Rank of 133, placing it in the bottom 48% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Core Viewpoint - Zoetis is highlighted as a feel-good stock with market-beating potential, especially following a significant drop in share price, making it an attractive investment opportunity [1][3][14] Group 1: Company Overview - Zoetis specializes in animal healthcare, providing medicines, vaccines, diagnostics, and precision health products for both companion animals and livestock [4] - The company has consistently outperformed the overall animal healthcare industry since 2014, driven by continuous innovation [4] - Approximately 55% of sales come from the United States, while 45% are generated internationally [7] Group 2: Product Innovation and Growth - The introduction of new osteoarthritis treatments, Librela and Solensia, has led to an 80% increase in sales in 2024, making them the company's fourth-largest franchise [5][6] - With a significant portion of pets likely to develop osteoarthritis, these products have substantial growth potential as pet owners increasingly invest in their pets' health [6] Group 3: Financial Performance - Zoetis has seen its net profit margin more than triple since 2012, with a return on invested capital (ROIC) of 21%, placing it in the top quintile of the S&P 500 [9] - The company's profitability allows for reinvestment in R&D and shareholder rewards, creating a positive feedback loop [10] Group 4: Shareholder Returns - Over the past decade, Zoetis has increased its dividend by 22% annually while reducing its total shares outstanding by 1% annually since 2014 [11][12] - The recent 36% drop in share price enhances the value of stock buybacks, allowing management to repurchase shares at a discount [12] Group 5: Valuation - Currently, Zoetis trades at a price-to-earnings ratio (P/E) of 29 and a dividend yield of 1.2%, both at historically attractive levels [13][14] - This combination of discounted price, steady growth, and rising profitability presents a once-in-a-decade investment opportunity [14]

Core Insights - Zoetis experienced a significant stock decline following disappointing quarterly results and subsequent analyst price target cuts [1][2] - The company's full-year 2025 revenue and earnings guidance fell short of consensus expectations, impacting investor sentiment [2] - Analysts from Morgan Stanley and Bank of America Securities reduced their price targets for Zoetis, while Barclays slightly increased its target [3][4] Financial Performance - Zoetis slightly exceeded analyst estimates for profitability and met revenue expectations in its fourth quarter [2] - The company's fourth quarter performance was characterized as neither disastrous nor outstanding, indicating stable but unimpressive growth [5] Analyst Actions - Morgan Stanley lowered its price target for Zoetis by $5 to $230, while Bank of America Securities cut its target from $205 to $200, both maintaining buy recommendations [3] - Barclays raised its fair value assessment from $242 to $244, also maintaining an overweight recommendation [4]

Group 1 - Zoetis Inc. reported Q4 earnings that met consensus expectations, but the stock experienced a sharp sell-off in the morning session before recovering in the afternoon [1] - The primary concern affecting the stock was the slowing growth in revenue [1] Group 2 - The company has a history of significant investment and innovation in the biotechnology sector, with key personnel having extensive experience in pharmaceuticals and biotech startups [1]

Part I [Business Overview](index=3&type=section&id=Item%201.%20Business) Zoetis is a global leader in the animal health industry, providing a diverse portfolio of products and services for companion animals and livestock [Overview and Operating Segments](index=3&type=section&id=Overview%20and%20Operating%20Segments) Zoetis is a global leader in animal health, focusing on medicines, vaccines, and diagnostics for eight core species, operating in U.S. and International segments - Zoetis is a global leader in the animal health industry, commercializing products across eight core species and seven major product categories[8](index=8&type=chunk) 2024 Revenue by Operating Segment | Operating Segment | Revenue (in millions) | Percentage of Total Revenue | | :--- | :--- | :--- | | United States (U.S.) | $5,074 | 55% | | International | $4,102 | 44% | 2024 Revenue Breakdown for Key Markets | Market | Revenue (in millions) | Companion Animal % | Livestock % | | :--- | :--- | :--- | :--- | | United States | $5,074 | 80% | 20% | | Total International | $4,102 | 54% | 46% | | Australia | $319 | 53% | 47% | | Brazil | $414 | 41% | 59% | | Canada | $277 | 62% | 38% | | China | $270 | 69% | 31% | | United Kingdom | $314 | 78% | 22% | [Products](index=5&type=section&id=Products) Zoetis's product portfolio is primarily composed of companion animal products (68% of revenue) and livestock products (31%), with top five lines contributing 41% of total revenue - Companion animal products represented approximately **68% of revenue**, while livestock products represented approximately **31%** for the year ended December 31, 2024[16](index=16&type=chunk)[17](index=17&type=chunk) - The top two product lines, Simparica/Simparica Trio and Apoquel/Apoquel Chewable, contributed approximately **15%** and **11% of revenue**, respectively. The top five product lines contributed approximately **41% of revenue** in 2024[27](index=27&type=chunk) - In 2024, the company divested its medicated feed additive product portfolio[19](index=19&type=chunk) - Key product categories include parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceuticals, and animal health diagnostics[21](index=21&type=chunk) [Operations and Strategy](index=8&type=section&id=Operations%20and%20Strategy) Zoetis operates globally in over 100 countries with 44% of 2024 revenue from international operations, supported by 4,050 sales specialists and a network of 22 manufacturing sites and over 110 CMOs - International operations accounted for **44% of total revenue** for the year ended December 31, 2024, with products sold in over 100 countries[30](index=30&type=chunk) - The sales organization consists of approximately **4,050 employees** as of December 31, 2024, who visit customers directly[33](index=33&type=chunk) - Sales to the company's largest customer, a U.S. veterinary distributor, represented approximately **14% of total revenue** for 2024[36](index=36&type=chunk) - The global manufacturing network consists of **22 company-operated sites** and over **110 third-party contract manufacturing organizations (CMOs)**[42](index=42&type=chunk)[45](index=45&type=chunk) [Research and Development](index=9&type=section&id=Research%20and%20Development) Zoetis invested $686 million in R&D in 2024, employing 1,600 people to manage over 300 programs focused on new product development and lifecycle innovation R&D Expenses (2022-2024) | Year | R&D Expense (in millions) | | :--- | :--- | | 2024 | $686 | | 2023 | $614 | | 2022 | $539 | - As of December 31, 2024, Zoetis employed approximately **1,600 people** in its global R&D operations[41](index=41&type=chunk) - R&D efforts comprise more than **300 programs**, focusing on both new product development and product lifecycle innovation[38](index=38&type=chunk) [Competition and Intellectual Property](index=10&type=section&id=Competition%20and%20Intellectual%20Property) Zoetis, the largest animal health company, faces intense competition from major players and generics, protecting its portfolio with approximately 5,500 granted patents despite key product patent expirations - Primary competitors include Boehringer Ingelheim Animal Health, Merck Animal Health, Elanco Animal Health, and IDEXX Laboratories[50](index=50&type=chunk) - The company holds approximately **5,500 granted patents** and has **1,450 pending patent applications** across more than 50 countries[54](index=54&type=chunk) - Patents for the active ingredient in Draxxin (tulathromycin) have expired in most major markets, leading to generic competition and a negative impact on sales[56](index=56&type=chunk) - Patents for the active ingredient of Excede/Naxcel (ceftiofur) have expired, with formulation patents expiring in the U.S. in July 2024[56](index=56&type=chunk) - The active ingredient patent for Cerenia has expired globally, and generic injectable versions are marketed in Europe, Canada, and Australia, with U.S. approval being pursued by competitors[56](index=56&type=chunk) [Regulatory Environment](index=11&type=section&id=Regulatory%20Environment) Zoetis's products are extensively regulated by agencies like the FDA, USDA, and EPA in the U.S., and EMA, MARA, and MAPA internationally, also adhering to global data privacy laws like GDPR - In the U.S., animal health products are regulated by the FDA (pharmaceuticals), USDA (biologicals), and EPA (pesticides)[60](index=60&type=chunk)[63](index=63&type=chunk)[65](index=65&type=chunk) - Key international regulatory bodies include the EMA in the EU, VMD in the U.K., MARA in China, MAPA in Brazil, and APVMA in Australia[70](index=70&type=chunk)[71](index=71&type=chunk)[72](index=72&type=chunk)[73](index=73&type=chunk)[74](index=74&type=chunk) - The company is subject to global data privacy laws, such as the EU's GDPR, which require enhanced handling of personal data[70](index=70&type=chunk)[78](index=78&type=chunk) [Human Capital and Environmental](index=13&type=section&id=Human%20Capital%20and%20Environmental) Zoetis employed approximately 13,800 people worldwide in 2024, achieving 86% employee engagement and incurring $28 million in environmental-related expenditures - As of December 31, 2024, the company had approximately **13,800 employees worldwide** (~6,700 in the U.S. and ~7,100 internationally)[81](index=81&type=chunk) - The employee engagement rate was **86% in 2024**, and the global voluntary attrition rate was stable at **8%**[84](index=84&type=chunk)[87](index=87&type=chunk) 2024 Environmental Expenditures | Category | Expenditure (in millions) | | :--- | :--- | | Environmental-related capital expenditures | ~$5 | | Other environmental-related expenditures | ~$23 | [Risk Factors](index=17&type=section&id=Item%201A.%20Risk%20Factors) The company faces diverse risks including intense competition, product dependence, manufacturing issues, extensive regulation, substantial indebtedness, and cybersecurity threats - The animal health industry is highly competitive, with pressure from large pharmaceutical companies, standalone businesses, and lower-priced generic alternatives[117](index=117&type=chunk) - The company's results are dependent on its top-selling products. The top five product lines contributed approximately **41% of revenue** in 2024, making them a significant concentration risk[118](index=118&type=chunk) - Manufacturing problems, such as supply chain disruptions or quality control failures at one of the **22 manufacturing sites** or over **110 CMOs**, could cause inventory shortages and recalls[153](index=153&type=chunk) - The business is subject to substantial regulation from agencies like the FDA, USDA, and EPA, and failure to comply can result in fines, production shutdowns, and product withdrawals[164](index=164&type=chunk) - As of December 31, 2024, the company had approximately **$6.7 billion of total unsecured indebtedness**, which could make it difficult to satisfy obligations and limit operational flexibility[204](index=204&type=chunk) - Cyberattacks pose a significant risk due to the company's reliance on complex IT systems, with potential for data breaches, disclosure of confidential information, and operational disruptions[182](index=182&type=chunk) [Cybersecurity](index=29&type=section&id=Item%201C.%20Cybersecurity) Zoetis implements a 'Defense in Depth' cybersecurity program aligned with NIST, overseen by the Board, with regular assessments and a 24/7 SOC - The company's cybersecurity program is aligned to the NIST Cybersecurity Framework (CSF) and uses a "Defense in Depth" security approach[217](index=217&type=chunk) - An independent third party conducts comprehensive assessments of the cybersecurity program approximately every **18 months**[217](index=217&type=chunk) - The Board of Directors, through the Audit Committee, oversees the company's enterprise risk management and information security program. The CISO presents updates at least annually to the full Board[223](index=223&type=chunk)[225](index=225&type=chunk) [Properties](index=30&type=section&id=Item%202.%20Properties) Zoetis operates approximately 184 owned and leased properties globally, totaling 11.4 million square feet, with the largest site in Kalamazoo, Michigan, supporting R&D and manufacturing - The company has approximately **184 properties** totaling **11.4 million square feet** worldwide[226](index=226&type=chunk) - The largest facility is an owned site in Kalamazoo, Michigan, which comprises approximately **1.6 million square feet** for R&D and manufacturing[226](index=226&type=chunk) [Legal Proceedings](index=30&type=section&id=Item%203.%20Legal%20Proceedings) Zoetis is involved in various legal proceedings, including product liability and intellectual property claims, which management believes are unlikely to have a material adverse effect - The company is subject to claims and litigation in the ordinary course of business, including product liability, competition law, and patent litigation[228](index=228&type=chunk) - Management believes the likelihood of a material adverse effect from current legal proceedings is remote, but acknowledges that litigation is inherently unpredictable[229](index=229&type=chunk) Part II [Market for Common Equity and Shareholder Matters](index=31&type=section&id=Item%205.%20Market%20for%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) Zoetis common stock is listed on the NYSE, with a new $6 billion share repurchase authorization approved in August 2024, and dividends declared at the Board's discretion - In August 2024, the Board of Directors authorized a new multi-year share repurchase program of up to **$6 billion**. As of December 31, 2024, **$5.6 billion** remained under this authorization[236](index=236&type=chunk) Issuer Purchases of Equity Securities (Q4 2024) | Period | Total Shares Purchased | Average Price Paid Per Share | | :--- | :--- | :--- | | Oct 1 - Oct 31, 2024 | 406,138 | $187.74 | | Nov 1 - Nov 30, 2024 | 1,235,190 | $175.49 | | Dec 1 - Dec 31, 2024 | 1,475,700 | $175.85 | | **Total** | **3,117,028** | **$177.26** | - The declaration and payment of dividends are at the discretion of the Board of Directors and depend on financial condition, operating results, and other factors[239](index=239&type=chunk) [Management's Discussion and Analysis (MD&A)](index=33&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) In 2024, Zoetis reported $9.26 billion in revenue, an 8% increase, with net income rising 6% to $2.49 billion, driven by strong U.S. segment growth and improved cost of sales [Results of Operations](index=39&type=section&id=Results%20of%20Operations) Zoetis achieved $9.26 billion in revenue in 2024, an 8% increase, with net income of $2.49 billion, driven by companion animal products and improved cost of sales Financial Performance Summary (2022-2024) | (MILLIONS OF DOLLARS) | 2024 | 2023 | 2022 | % Change 24/23 | | :--- | :--- | :--- | :--- | :--- | | Revenue | $9,256 | $8,544 | $8,080 | 8% | | Net income attributable to Zoetis | $2,486 | $2,344 | $2,114 | 6% | | Adjusted net income (a) | $2,693 | $2,457 | $2,297 | 10% | - Operational revenue growth of **11% in 2024** was primarily driven by price growth of approximately **6%**, volume growth from new products of **3%**, and volume growth from key dermatology products of **2%**[314](index=314&type=chunk) - Cost of sales as a percentage of revenue decreased from **30.0% in 2023 to 29.4% in 2024**, mainly due to price increases, favorable product mix, and lower freight costs[316](index=316&type=chunk) - R&D expenses increased by **12% to $686 million in 2024**, driven by higher project investments and compensation-related costs[321](index=321&type=chunk) [Operating Segment Results](index=42&type=section&id=Operating%20Segment%20Results) In 2024, the U.S. segment revenue grew 11% to $5.07 billion, while the International segment revenue increased 5% (10% operationally) to $4.10 billion, both driven by companion animal products - **U.S. Segment:** Revenue grew **11% to $5,074 million**. Companion animal revenue increased **15%**, driven by Simparica Trio, OA pain products (Librela, Solensia), and dermatology products. Livestock revenue declined **1%**. Segment earnings increased **17% to $3,336 million**[335](index=335&type=chunk)[336](index=336&type=chunk)[341](index=341&type=chunk) - **International Segment:** Revenue grew **5% (10% operationally) to $4,102 million**. Companion animal operational revenue grew **13%**, while livestock operational revenue grew **8%**. Foreign exchange had a negative impact of **5% ($210 million)**. Segment earnings increased **4% (11% operationally) to $2,118 million**[337](index=337&type=chunk)[338](index=338&type=chunk)[341](index=341&type=chunk) [Non-GAAP Financial Measures](index=38&type=section&id=Non-GAAP%20Financial%20Measures) Management uses non-GAAP measures like 'operational growth' and 'adjusted net income' to assess core performance, with adjusted net income increasing 10% to $2.69 billion in 2024 Reconciliation of GAAP Net Income to Non-GAAP Adjusted Net Income | (MILLIONS OF DOLLARS) | 2024 | 2023 | % Change | | :--- | :--- | :--- | :--- | | GAAP reported net income attributable to Zoetis | $2,486 | $2,344 | 6% | | Purchase accounting adjustments—net of tax | 109 | 127 | (14%) | | Acquisition and divestiture-related costs—net of tax | 14 | 7 | * | | Certain significant items—net of tax | 84 | (21) | * | | **Non-GAAP adjusted net income** | **$2,693** | **$2,457** | **10%** | Reconciliation of GAAP Diluted EPS to Non-GAAP Adjusted Diluted EPS | | 2024 | 2023 | % Change | | :--- | :--- | :--- | :--- | | GAAP reported EPS attributable to Zoetis—diluted | $5.47 | $5.07 | 8% | | Purchase accounting adjustments—net of tax | 0.24 | 0.28 | (14%) | | Acquisition and divestiture-related costs—net of tax | 0.03 | 0.02 | 50% | | Certain significant items—net of tax | 0.18 | (0.05) | * | | **Non-GAAP adjusted EPS—diluted** | **$5.92** | **$5.32** | **11%** | [Liquidity and Capital Resources](index=47&type=section&id=Analysis%20of%20financial%20condition%2C%20liquidity%20and%20capital%20resources) Zoetis maintained strong liquidity in 2024 with $1.99 billion in cash, generating $2.95 billion from operations, and managing $6.57 billion in debt, supported by a $1.0 billion undrawn credit facility Selected Liquidity Measures (as of Dec 31) | (MILLIONS OF DOLLARS) | 2024 | 2023 | | :--- | :--- | :--- | | Cash and cash equivalents | $1,987 | $2,041 | | Working capital | $2,574 | $4,454 | | Long-term debt (including current portion) | $6,570 | $6,564 | - Net cash provided by operating activities increased to **$2,953 million in 2024** from **$2,353 million in 2023**, primarily due to higher net income and favorable changes in working capital[377](index=377&type=chunk) - The company has a **$1.0 billion senior unsecured revolving credit facility** expiring in December 2027, which was undrawn as of December 31, 2024[382](index=382&type=chunk)[551](index=551&type=chunk) - During 2024, **10.4 million shares** were repurchased for **$1.8 billion**[397](index=397&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=53&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) Zoetis is exposed to foreign exchange and interest rate risks, hedging with derivatives, with a 10% USD change impacting CTA by $91 million and a 100-basis point SOFR increase raising interest expense by $3 million - The company's primary net foreign currency exposures are the Australian dollar, Brazilian real, British pound, Canadian dollar, Chinese renminbi, and euro[405](index=405&type=chunk) - A hypothetical **10% change** in the U.S. dollar against all other currencies would change the amount recorded in cumulative translation adjustment (CTA) related to net investment hedges by approximately **$91 million**[407](index=407&type=chunk) - The company's outstanding debt is predominantly fixed-rate. However, interest rate swaps effectively convert a portion of this debt to a variable rate based on SOFR. A **100-basis point increase** in SOFR would increase annual interest expense by approximately **$3 million**[410](index=410&type=chunk)[411](index=411&type=chunk) [Financial Statements and Supplementary Data](index=54&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) This section presents Zoetis's audited consolidated financial statements for 2024, including the auditor's unqualified opinion and critical audit matters regarding tax benefits and rebate accruals [Report of Independent Registered Public Accounting Firm](index=55&type=section&id=Report%20of%20Independent%20Registered%20Public%20Accounting%20Firm) KPMG LLP issued an unqualified opinion on Zoetis's 2024 financial statements and internal controls, highlighting critical audit matters for unrecognized tax benefits and U.S. segment rebate accruals - KPMG LLP issued an unqualified opinion, stating the financial statements are presented fairly in all material respects[419](index=419&type=chunk) - A critical audit matter was the evaluation of gross unrecognized tax benefits of **$213 million**, which required complex judgment and specialized tax skills to assess[424](index=424&type=chunk)[425](index=425&type=chunk) - A second critical audit matter was assessing the U.S. segment's rebate accrual, due to the variety of programs and challenging auditor judgment required to estimate the accrual[427](index=427&type=chunk)[428](index=428&type=chunk) [Consolidated Financial Statements](index=58&type=section&id=Consolidated%20Financial%20Statements) The 2024 consolidated financial statements show $9.256 billion in revenue, $2.486 billion in net income, $14.237 billion in total assets, and $2.953 billion in cash from operations Consolidated Statement of Income (Year Ended Dec 31, 2024) | (MILLIONS OF DOLLARS) | Amount | | :--- | :--- | | Revenue | $9,256 | | Income before provision for taxes on income | $3,133 | | Net income attributable to Zoetis Inc. | $2,486 | | Diluted Earnings per share | $5.47 | Consolidated Balance Sheet (As of Dec 31, 2024) | (MILLIONS OF DOLLARS) | Amount | | :--- | :--- | | Total current assets | $5,986 | | Total assets | $14,237 | | Total current liabilities | $3,412 | | Total liabilities | $9,467 | | Total Zoetis Inc. equity | $4,770 | Consolidated Statement of Cash Flows (Year Ended Dec 31, 2024) | (MILLIONS OF DOLLARS) | Amount | | :--- | :--- | | Net cash provided by operating activities | $2,953 | | Net cash used in investing activities | ($315) | | Net cash used in financing activities | ($2,660) | | Net decrease in cash and cash equivalents | ($54) | [Selected Notes to Consolidated Financial Statements](index=63&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) The notes detail revenue disaggregation, the 2024 divestiture of medicated feed additive portfolio for $292 million, a contested IRS audit for $450 million, and $6.65 billion in outstanding long-term debt - On October 31, 2024, the company completed the divestiture of its medicated feed additive product portfolio to Phibro Animal Health for net proceeds of **$292 million**, resulting in a pre-tax loss of **$25 million**[525](index=525&type=chunk) - The IRS is auditing tax years 2017-2018 and has proposed adjustments related to the one-time mandatory deemed repatriation tax. The proposed additional tax liability is approximately **$450 million**, which Zoetis disagrees with and is protesting[547](index=547&type=chunk)[548](index=548&type=chunk) - As of December 31, 2024, the company had **$6.65 billion** in principal amount of senior notes outstanding, with maturities ranging from 2025 to 2050[558](index=558&type=chunk)[560](index=560&type=chunk) - Sales to the largest customer, a U.S. veterinary distributor, accounted for approximately **14% of total revenue** in 2024[521](index=521&type=chunk) [Controls and Procedures](index=93&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management, including the CEO and CFO, concluded that Zoetis's disclosure controls and internal control over financial reporting were effective as of December 31, 2024, a conclusion affirmed by KPMG LLP - The CEO and CFO concluded that the company's disclosure controls and procedures were effective as of December 31, 2024[650](index=650&type=chunk) - Management concluded that the company's internal control over financial reporting was effective as of December 31, 2024, a conclusion audited and affirmed by KPMG LLP[651](index=651&type=chunk) Part III [Directors, Executive Officers, Corporate Governance, and Other Matters](index=94&type=section&id=Items%2010-14) This section incorporates by reference information from the company's 2025 Proxy Statement regarding directors, executive officers, corporate governance, executive compensation, security ownership, and principal accountant fees - Information regarding directors, executive officers, corporate governance (Item 10), executive compensation (Item 11), security ownership (Item 12), certain relationships and director independence (Item 13), and principal accountant fees (Item 14) is incorporated by reference from the registrant's 2025 Proxy Statement[4](index=4&type=chunk)[657](index=657&type=chunk)[658](index=658&type=chunk)[659](index=659&type=chunk)[660](index=660&type=chunk)[662](index=662&type=chunk) Part IV [Exhibits and Financial Statement Schedules](index=95&type=section&id=Item%2015.%20Exhibit%2C%20Financial%20Statement%20Schedules) This section lists financial statements, schedules, and exhibits filed with the Form 10-K, including key corporate documents and debt agreements, many incorporated by reference - This section provides a comprehensive index of all exhibits filed with or incorporated by reference into the Form 10-K, including the Restated Certificate of Incorporation, Amended and Restated By-laws, various debt indentures, and management compensation plans[667](index=667&type=chunk)[669](index=669&type=chunk)[670](index=670&type=chunk)

Core Viewpoint - Zoetis, Inc. reported strong fourth-quarter 2024 results with adjusted earnings of $1.40 per share, exceeding estimates, and total revenues of $2.32 billion, also surpassing expectations [1][2]. Financial Performance - Adjusted earnings for Q4 2024 were $1.40 per share, up from $1.24 in the same quarter last year [1]. - Total revenues increased by 5% year over year to $2.32 billion, compared to $2.21 billion in the prior year [2]. - For the full year 2024, adjusted earnings were $5.92 per share, up from $5.32, with total revenues growing 8% to $9.26 billion [10]. Segment Performance - U.S. segment revenues rose 4% year over year to $1.257 billion, but fell short of estimates [4]. - Companion animal product sales in the U.S. increased by 7% to $1.01 billion, driven by key products like Librela and Solensia [5]. - Livestock product sales in the U.S. decreased by 8% to $249 million, primarily due to divestitures [6]. - International segment revenues grew by 6% year over year to $1.039 billion, exceeding estimates [7]. - Companion animal product sales internationally rose by 11% to $562 million, supported by growth in several key products [8]. - Livestock product sales internationally were flat year over year but grew 6% operationally to $477 million [9]. Future Guidance - For 2025, Zoetis expects adjusted earnings in the range of $6.00 to $6.10 per share, with projected revenues between $9.225 billion and $9.375 billion, indicating operational growth of 2-4% [11][12].

Financial Data and Key Metrics Changes - The company reported full-year revenue of $9.3 billion, growing 8% on a reported basis and 11% operationally, with 6% driven by price and 5% from volume [30] - Adjusted net income grew 10% on a reported basis and 15% operationally to $2.7 billion [31] - Full-year adjusted gross margins were 70.7%, growing 50 basis points on a reported basis [57] Business Line Data and Key Metrics Changes - The companion animal portfolio grew 14% operationally, while the livestock portfolio saw a 5% operational revenue growth [11][21] - The Simparica franchise generated $1.4 billion in revenue, growing 28% operationally, with Simparica Trio exceeding $1 billion in global revenue [31] - The osteoarthritis pain franchises, including Librela and Solensia, reported combined revenue of $581 million, growing 80% operationally [31] Market Data and Key Metrics Changes - In the US, revenue grew 11%, while international revenue grew 10% operationally [10][35] - The international livestock portfolio grew 8% operationally to $1.9 billion in sales for the year [44] - The US livestock business declined 1% due to the MFA divestiture, but organic operational growth was 6% [40] Company Strategy and Development Direction - The company aims for continued above-market growth in the mid to high single-digit range for 2025 and beyond, driven by scientific innovation and commercial excellence [11][25] - A strategic divestiture of the medicated feed additive product portfolio was made to enhance operational focus and prioritize high-growth areas [22] - The company is committed to balancing strategic investments in innovation while delivering long-term value for shareholders [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining growth due to the diversity of the business model and strong underlying demand in the animal health industry [12][24] - The company anticipates organic operational revenue growth of 6% to 8% in 2025, with continued strong performance from the companion animal business [23][63] - Management highlighted the importance of the human-animal bond and the aging pet population as key drivers for future growth [109] Other Important Information - The company repurchased $1.9 billion of shares in 2024, the most in its history, and increased its dividend rate by 15% [60][61] - The guidance for 2025 reflects foreign exchange headwinds of approximately $250 million to revenue and $50 million to adjusted net income [62] Q&A Session Summary Question: Insights on competition and guidance adjustments - Management acknowledged competition in the dermatology segment and emphasized the vast opportunity remaining in the market, with significant untreated populations [80][81] - Investments in key brands and education for veterinarians were highlighted as strategies to maintain growth despite competition [82] Question: Updates on Librela and its market response - The launch of Librela was described as highly successful, with veterinarians responding positively to updated prescribing information [88][89] - Management confirmed that no new products are included in the 2025 guidance, but strong growth is expected in the OA pain category [87] Question: Revenue cadence and R&D investments - Management indicated a stronger first half of 2025 compared to the second half, factoring in potential competition [98] - R&D investments are expected to align with pipeline progress rather than being a fixed leverageable line item [101] Question: Trends in pet population growth post-COVID - Management noted that the pet population is expected to remain stable, with strong growth drivers from the human-animal bond and an aging pet population [109][110] Question: Upside risks to guidance and total addressable market for new products - Management confirmed that new product approvals are not factored into guidance, but expressed excitement about the diverse portfolio and strong demand [115][118]